跳至主要内容
临床试验/NCT04648592
NCT04648592Unknown不适用

Impact of Salt Intake on Gut Microbiota, Th17 Immune Response and Endothelial Function in Hypertensive Patients

Hospital Clínico Universitario de Valladolid1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2020年12月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
25
试验地点
1
主要终点
Absolute change in lymphocyte subset counts

研究概览

简要总结

Hypertension is a significant cardiovascular risk factor which affects 45% of the adult population. Salt intake is essential in the development and progression of hypertension. A reduction in salt intake is associated with a reduction in blood pressure and a 25% lower risk of suffering a cardiovascular event. The mechanisms involved in the association between salt intake and blood pressure are a topic of discussion. Increased salt intake can modify cardiovascular function, inducing endothelial dysfunction, modyfing the activity of the immune system and increasing inflammation or oxidative stress.

In recent years, dietary salt intake has been linked to intestinal depletion of certain genera of bacteria such as Lactobacillus. Tryptophan metabolites formed by these bacteria have been shown to modulate the activity of pro-inflammatory cells such as Th17/CD4+, interleukin 17a producing cells. Studies in animal models have demonstrated that interleukin 17a is able to raise blood pressure by hindering endothelium-dependent vasodilation mechanisms. It is also able to cause sodium and water retention, increase albuminuria, induce renal microvascular injury and vasoconstriction and promote vascular stiffening, cardiac hypertrophy and fibrosis.

The main objective of this trial is to describe the relationship between salt intake, gut commensal microbiota, Th17 activity, endothelial dysfunction and blood pressure evolution in a sample of patients with essential hypertension.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

Trial participants, care providers and study investigators will be blinded to assigned interventions.

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age ≥18 years.
  • •Diagnosis of primary hypertension on treatment for at least 12 months with an ACEI or ARB-II in monotherapy.
  • •Able to understand the study objectives and to provide written informed consent.

排除标准

  • •Severe hypertension, defined as a sitting systolic blood pressure ≥200 mmHg, a sitting diastolic blood pressure ≥115 mmHg or a maximum-minimum difference of ≥20 mmHg in systolic blood pressure or ≥10 mmHg in diastolic blood pressure between the right and left arms after three measurements on each arm.
  • •Suggestive symptoms of secondary hypertension, such as abrupt onset hypertension, age <30 years, advanced end organ damage, new-onset diastolic hypertension in the elderly,
  • •Treated with antihypertensive drugs other than ACEIs or ARBs.
  • •Use of drugs that affect diuresis or natriuresis.
  • •Poorly controlled type 1 or 2 diabetes, defined as a fasting blood glucose ≥200 mg/dl or HbA1c ≥9%.
  • •History of cardiovascular disease, defined as acute myocardial infarction, ischemic transient attack or stroke, congestive heart failure, peripheral vascular disease or cardiac arrhythmias.
  • •Chronic obstructive pulmonary disease.
  • •Liver or kidney disease.
  • •Pregnant or lactating women.
  • •Legal incapacity or impossibility to understand the study objectives.

研究组 & 干预措施

Intervention

Experimental

Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral salt supplements (9 grams) to achieve an overall daily sodium intake of 200 mmol.

干预措施: Low salt diet plus sodium chloride supplements (Dietary Supplement)

Control

Placebo Comparator

Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral placebo supplements to achieve an overall daily sodium intake of 50 mmol.

干预措施: Low salt diet plus placebo (Dietary Supplement)

结局指标

主要结局

Absolute change in lymphocyte subset counts

时间窗: 30 days

Lymphocyte subset counts

次要结局

  • Relative change in body composition assessed by electrical bioimpedance(30 days)
  • Absolute change in peak and average 24h ambulatory blood pressure measurement(30 days)
  • Absolute change in endothelial function(30 days)
  • Relative change in gut microbiota composition daily total salt(30 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Armando Coca Rojo

Principal Investigator

Hospital Clínico Universitario de Valladolid

研究点 (1)

Loading locations...

相似试验